Medroxyprogesterone acetate in the management of cancer cachexia

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 8, 2009, Pages 1359-1366

  Madeddu, Clelia ^a   Macciò, Antonio ^a   Panzone, Filomena ^a   Tanca, Francesca Maria ^a   Mantovani, Giovanni ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cancer cachexia; Lean body mass; Medroxyprogesterone acetate; Proinflammatory cytokines

Indexed keywords

CELECOXIB; GESTAGEN; INTERLEUKIN 1; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANOREXIA; BODY FAT; BODY WEIGHT; BONE METABOLISM; CACHEXIA; CANCER CACHEXIA; CLINICAL TRIAL; CUSHING SYNDROME; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMUR HEAD NECROSIS; HUMAN; MYOPATHY; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PEPTIC ULCER; PERIPHERAL EDEMA; QUALITY OF LIFE; REVIEW; STRIA; WEIGHT GAIN;

ANIMALS; CACHEXIA; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASMS;

EID: 67649745894     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902960162     Document Type: Review

References (48)

1. Argiles JM, Lopez-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008;13:73-78
2. Mulligan K, Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol 2002;85:151-159 (Pubitemid 34887981)
3. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002;85:51-66 (Pubitemid 34887972)
4. Mantovani G, Macciò A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008;24:305-313
5. Ng EH, Lowry SF. Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol Oncol Clin North Am 1991;5:161-184
6. Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev 1997;17:477-498 (Pubitemid 27376498)
7. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008;27:793-799 •• This is a new and comprehensive definition of cachexia which was agreed upon by an expert panel during a Consensus Conference in Washington DC in 2006. It is presently to be considered the most widely accepted clinical definition encompassing different diseases.
8. McNamara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology of cancer cachexia. JPEN J Parenter Enteral Nutr 1992;16:50S-55S
9. Mantovani G, Macciò A, Versace R, et al. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. J Mol Med 1995;73:409-416 •• These are the first papers to have established a strict and causal correlation between serum levels of pro-inflammatory cytokines and cancer cachexia.
10. Mantovani G, Macciò A, Esu S, et al. Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients. Int J Oncol 1994;5:1211-1217 •• These are the first papers to have established a strict and causal correlation between serum levels of proinflammatory cytokines and cancer cachexia. (Pubitemid 24357461)
11. Mantovani G, Macciò A, Lai P, et al. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncol 1998;9:99-106 (Pubitemid 29079042)
12. Strassmann G, Kambayashi T. Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. Cytokines Mol Ther 1995;1:107-113
13. Mantovani G, Macciò A, Lai P, et al. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998;25:45-52 (Pubitemid 28268504)
14. Laviano A, Russo M, Freda F, Rossi-Fanelli F. Neurochemical mechanisms for cancer anorexia. Nutrition 2002;18:100-105 (Pubitemid 34097728)
15. Plata-Salaman CR. Cytokine-induced anorexia. Behavioral, cellular, and molecular mechanisms. Ann NY Acad Sci 1998;856:160-170 (Pubitemid 28517348)
16. Jennische E, Skottner A, Hansson HA. Satellite cells express the trophic factor IGF-I in regenerating skeletal muscle. Acta Physiol Scand 1987;129:9-15 (Pubitemid 17037758)
17. Ng EH, Rock CS, Lazarus DD, et al. Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia. Am J Physiol 1992;262:R426-31
18. Argiles JM, Lopez-Soriano J, Busquets S, Lopez-soriano FJ. Journey from cachexia to obesity by TNF. FASEB J 1997;11:743-751 (Pubitemid 27349559)
19. Hauner H, Petruschke T, Russ M, et al. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995;38:764-771
20. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51 (Pubitemid 32466842)
21. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999;10:19-29 (Pubitemid 129505535)
22. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212-17
23. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992;89:1681-1684
24. Tominaga T, Abe O, Ohshima A, et al. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer 1994;30A:959-964 (Pubitemid 24256243)
25. Mantovani G, Macciò A, Bianchi A, et al. Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995;25:135-141 •• The first clinical study showing a correlation between the clinical efficacy of a progestagen (megestrol acetate) and the decrease of serum levels of proinflammatory cytokines.
26. Mantovani G, Macciò A, Esu S, et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 1997;33:602-607 •• The first laboratory study showing that the administration in-vitro of medroxiprogesterone acetate induced a downregulation of the production/release of proinflammatory cytokines. (Pubitemid 27223745)
27. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277-283 (Pubitemid 38523308)
28. McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994;265:99-102 (Pubitemid 24341663)
29. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl 1):7-16 (Pubitemid 37506058)
30. Diament MJ, Peluffo GD, Stillitani I, et al. Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer Invest 2006;24:126-131
31. Yamashita JI, Ogawa M. Medroxyprogesterone acetate and cancer cachexia: interleukin-6 involvement. Breast Cancer 2000;7:130-135
32. Kurebayashi J, Yamamoto S, Otsuki T, Sonoo H. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br J Cancer 1999;79:631-636 (Pubitemid 29046247)
33. Koubovec D, Berghe WV, Vermeulen L, et al. Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol 2004;221:75-85 (Pubitemid 38829725)
34. Mantovani G, Macciò A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001;61:499-514 (Pubitemid 32368064)
35. Downer S, Joel S, Allbright A, et al. A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1993;67:1102-1105 (Pubitemid 23147511)
36. Simons JP, Schols AM, Hoefnagels JM, et al. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer 1998;82:553-560 •• Probably the most significant randomized clinical trial on medroxi progesteron acetate in cancer cachexia. (Pubitemid 28112995)
37. Neri B, Garosi VL, Intini C. Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs 1997;8:459-465 (Pubitemid 27310914)
38. Cerchietti LC, Navigante AH, Peluffo GD, et al. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 2004;27:85-95 •• This is a very interesting study because it was one of the first to use a combined treatment approach against cancer cachexia. (Pubitemid 38050252)
39. Mantovani G, Macciò A, Madeddu C, et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 2006;15:1030-1034 •• This was the first phase II study of a multi-targeted combined treatment approach which was shown to be effective in cancer cachexia by assessing several clinical, nutritional, functional, laboratory and quality of life parameters. (Pubitemid 43823535)
40. Mantovani G. The current management of cancer cachexia. Milan: Springer-Verlag, 2006
41. Ottery FD, Walsh D, Strawford A. Pharmacologic management of anorexia/cachexia. Semin Oncol 1998;25:35-44 (Pubitemid 28268503)
42. Femia RA, Goyette RE. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs 2005;19:179-187 (Pubitemid 40994233)
43. Ishida Y, Mine T, Taguchi T. Effect of progestins with different glucocorticoid activity on bone metabolism. Clin Endocrinol (Oxf) 2008;68:423-428 (Pubitemid 351257862)
44. Ishida Y, Ishida Y, Heersche JN. Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis. Osteoporos Int 2002;13:601-605 (Pubitemid 34885849)
45. Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 1983;32:1511-1518
46. Selman PJ, Wolfswinkel J, Mol JA. Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog. Steroids 1996;61:133-137 (Pubitemid 26084147)
47. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998;55:675-688 (Pubitemid 28203774)
48. Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 2001;12:289-300 • This is a very interesting, albeit not very recent, review on high-dose progestins for the treatment of cancer anorexia-cachexia syndrome. (Pubitemid 32288683)